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1. Introduction 
The TNF receptor superfamily member 11A known as receptor activator of nuclear factor κB 
(RANK/TNFRSF11A), its ligand RANKL (TNFSF11) and the decoy receptor for RANKL 
called osteoprotegerin (OPG/TNFRSF11B) have been shown to be key regulators of bone 
remodeling (Simonet et al., 1997; Lacey et al., 1998; Theoleyre et al., 2004). Indeed, RANKL 
mediates osteoclastogenesis and activates mature osteoclasts, whereas OPG negatively 
regulates RANKL binding to RANK, reduces the half-life of membranous RANKL and 
finally inhibits bone resorption by osteoclasts (Tat et al., 2006). Together with such part in 
bone, the RANK/RANKL axis is also involved in a variety of physiologic functions. 
Certainly, the RANK/RANKL axis controls the lymph-node organogenesis, the thymic 
medullary epithelial cells differentiation, the central thermoregulation, the formation of 
lactating mammary gland during pregnancy and the proliferation of epithelial cells of the 
epidermo-pilosebaceous unit (Dougall et al., 1999; Kong et al., 1999; Fata et al., 2000; Rossi et 
al., 2007; Hanada et al., 2009; Duheron et al., 2011). 
In parallel to its physiologic functions, the RANK/RANKL axis has been also implicated in 
several pathologies, in particular in tumors with bone connections as bone primitive tumors 
and bone metastasis forming tumors. Thus, functional RANK expression has been reported 
in cells of different tumors, such as prostate and breast cancers, osteosarcoma and 
melanoma (Jones et al., 2006; Wittrant et al., 2006; Mori et al. 2007a, b, c). Moreover, RANKL 
was shown to trigger the migration of these RANK-expressing cells (Jones et al., 2006; Mori 
et al., 2007a). According to these observations, the RANK/RANKL axis might have a great 
impact on melanoma development. The aim of the present chapter is to discuss, based on 
the actual knowledge, the feasibility of targeting RANK/RANKL axis for the treatment of 
melanoma. 
2. RANK/RANKL axis interest for melanoma treatment 
2.1 RANK/RANKL, skin-appendages and skin 
The RANK/RANKL axis has emerged as an important physiologic player in epithelial cell 
growth and differentiation. First evidences came from expression patterns of both RANK 
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and RANKL during the development of skin-appendages as hairs, teeth and mammary 
glands (Ohazama et al., 2004; Mikkola, 2008; Tanos & Brisken, 2008; Duheron et al., 2011). 
Regarding mammary glands, RANK and its ligand are both expressed in epithelial cells 
and control the development of a lactating mammary gland during pregnancy. In absence 
of RANK/RANKL signaling, the formation of lobulo-alveolar structures, necessary to a 
functional lactating mammary gland, is severely impaired leading to milk secretion 
defect. 
Concerning hairs, RANK is expressed by the hair follicle germ, bulge stem cells and 
epidermal basal cells. Interestingly, these cell-types are implicated in the renewal of the 
epidermo-pilosebaceous unit. Its ligand (RANKL) is actively transcribed by the hair follicle 
at initiation of its growth phase, providing a mechanism for RANK-expressing stem cell 
engagement and hair-cycle entry. Mice deficient in RANKL are unable to initiate a new 
growth phase of the hair cycle and display arrested epidermal homeostasis. Furthermore, 
transgenic mice overexpressing RANK in the hair follicle or administration of recombinant 
RANKL both activate the hair cycle and epidermal growth. Finally, RANK signaling is 
dispensable for the formation of the stem cell compartment and the induction of hair follicle 
mesenchyme, but RANK-RANKL axis regulates hair renewal and epidermal homeostasis 
and provides a link between these two activities. 
The RANK/RANKL axis also plays essential roles on immune system including 
participation in T-cell/dendritic cell communications (Leibbrandt & Penninger, 2010). 
Interestingly, RANKL over-expression in keratinocytes results in functional alterations of 
epidermal dendritic cells and systemic increases of regulatory CD4(+)CD25(+) T cells. 
Consequently, epidermal RANKL expression can modify dendritic cell functions to 
maintain the number of peripheral CD4(+)CD25(+) regulatory T cells. Finally, 
environmental stimuli at the skin level can rewire the local and systemic immune system by 
means of RANKL. 
2.2 RANK/RANKL and bone-associated cancers 
Since the late nineteenth century, it has been thought that the microenvironment of the local 
host tissue actively participates in the tendency of some cancers to metastasize to specific 
organs (Paget, 1889). However, the specific factors involved are still unknown. 
Bones are continuously remodeled throughout life by two complementary processes: bone 
matrix formation (apposition) regulated by osteoblasts and bone resorption managed by 
osteoclasts. The precise inter-relation between osteoblasts and osteoclasts leading to 
osteoclastogenesis is only partly deciphered. The discovery of certain key factors involved in 
the control of osteoclastogenesis has moved bone research into a new era. Current findings 
have revealed that the RANKL/RANK/OPG molecular triad constitutes a key regulator for 
both normal and pathological bone metabolism (Brown et al., 2001; Goltzman, 2001; Chen, et 
al. 2006). The prevention of different tumors metastases inheritance in bone by RANKL 
inhibitors [i.e., OPG or soluble RANK (sRANK) or RANK blocking antibodies (RANK-Fc)] 
in established animal models of bone metastases, highlights the critical role of this triad in 
cancer-induced bone manifestations (Zhang et al., 2001, 2003; Corey et al., 2005; Whang et 
al., 2005; Mountzios et al., 2007; Canon et al, 2008). Interestingly, such anti-tumor effects 
appear to be restricted to bone models. Indeed, such effects have not been observed in any 
other models, including classical subcutaneous models (Zhang et al., 2001, 2003). Thus, it 
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was first believed that anti-tumor effects induced by RANKL/RANK interaction blockage 
were the result of an indirect effect via osteoclasts. 
In turn, functional RANK expression was recently reported in bone-associated tumors, more 
precisely in cells of breast cancer, prostate cancer, osteosarcoma and malignant melanoma 
(Jones et al., 2006; Wittrant et al., 2006; Mori et al., 2007a, b, c; Armstrong et al., 2008). 
According to the fact that RANK-expressing tumor cells migration was induced by RANKL 
stimulation (Armstrong et al., 2008; Jones et al., 2006; Mori et al., 2007a), the direct effect of 
RANKL on RANK-expressing tumor cells was in fine disclosed. Consequently, RANKL 
works, in bone, as one of the “soil” factors of Paget’s theory (Fig. 1). 
 
 
RANKL RANK OPG
 
Fig. 1. Schematic representation of the putative interactions between RANK-expressing 
tumor cells (i.e., prostate cancer, breast cancer and malignant melanoma) and bone cells 
(osteoblasts and osteoclasts) in the tumoral bone microenvironment 
In fact, RANK-expressing tumor cells would preferentially targeted bone microenvironment 
where RANKL concentration is elevated. In the bone tumoral environment, RANKL 
produced by osteoblasts and bone stromal cells has two potential targets: on the one hand 
the osteoclast precursor and the osteoclast, and on the other hand the RANK-expressing 
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tumor cell. So RANKL acts as a “soil” factor that facilitates cancer metastasis settlement in 
bone by activating both kinds of RANK-expressing cells.  
2.3 Melanomas: skin tumors with bone metastasis 
Melanoma belongs to the large family of skin tumors (see WHO classification of skin 
tumors: In Pathology and Genetics of Skin Tumors edited by P.E. LeBoit, G. Burg, D. 
Weedon and A. Sarasin, IARC Press, Lyon, 2006). From a clinical and public health point of 
view, malignant melanomas are the most important group of skin tumors. Although less 
common than basal and squamous cell tumors of the skin, they are much more often fatal, 
due to their intrinsic propensity to metastasis. The major environmental risk factor for 
melanoma is recurrent expositions to high-doses of UV radiations. Endogenous factors are 
often combined as genetic susceptibility. Bone metastasis is a poor prognostic for patient 
and corresponds to the ultimate stage of the pathology. The precise implication of 
RANK/RANKL axis in the bone metastatic process has been controversial but nowadays it 
seems clear that this signalization plays successive parts in this complex process. Indeed, 
RANK/RANKL axis is implicated in tumor cell migration (as previously described) and 
later in tumor cell settlement in the bone microenvironment and induction of osteolysis 
(Mundy, 2002; Jones et al., 2006). Consequently, targeting RANK/RANKL signalization 
might be a promising strategy to prevent melanoma bone metastasis and subsequent 
damages.  
2.4 Targeting RANK/RANKL axis for melanoma treatment: benefit/risk 
According to the disastrous consequences of melanoma metastasis in term of patient 
survival, any treatments that enable confinement of tumor cells to their initial site has to be 
considered as therapeutically beneficial. RANK/RANKL inhibitors, due to the implication 
of RANK/RANKL axis in metastatic process, are so potentially highly relevant therapeutic 
agents for melanoma. They may reduce the incidence of metastasis and synergized with 
anti-tumoral drugs. Indeed, several studies has been reported such beneficial effect of OPG 
(Lamoureux et al., 2007), OPG peptide (Heymann et al., 2005), RANK-Fc (Lamoureux et al., 
2008) and Denosumab (fully human anti-RANKL antibody) (Abrahamsen et al., 2005) as 
RANK/RANKL inhibitors for the treatment of bone-associated cancers. 
However, as presented above, the RANK/RANKL signalization is implicated in various 
physiological processes during development and takes part to the immune response.  
So targeting this pathway in children may have developmental consequences that need to  
be evaluated. Moreover, whatever the age of the patient, the potential impact of such 
inhibitor on the immune response as to be taken into account and may in fine limited their 
use.  
3. Conclusion 
The use of drugs targeting the RANK/RANKL axis in melanoma appears to be a promising 
strategy to reduce the mortality of this skin cancer. Such drugs should reduce the metastatic 
process and enforce the action of classical anti-tumoral treatment. However, further studies 
will be necessary to evaluate the impact of these drugs on RANK/RANKL signaling 
physiological functions, more specifically during growth, and to deal with these drugs 
potential wrong impact on immune system. 
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